Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
16:22 | Bioventus gains after raising annual sales, profit forecasts | 1 | Reuters | ||
13:37 | Bioventus Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
13:33 | Bioventus Inc. - 8-K, Current Report | - | SEC Filings | ||
29.04. | Bioventus, Inc.: Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024 | 1 | GlobeNewswire (USA) | ||
25.03. | Bioventus CFO sells over $29k in company stock | 1 | Investing.com | ||
20.03. | Bioventus exec sells over $17k in company stock | 1 | Investing.com | ||
20.03. | Bioventus executive sells over $6,600 in company stock | 1 | Investing.com | ||
20.03. | Bioventus Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
13.03. | Bioventus shares target raised to $9 on solid Q4 performance | 1 | Investing.com | ||
13.03. | Earnings call: Bioventus Inc. reports solid Q4 growth, optimistic 2024 outlook | 1 | Investing.com | ||
12.03. | Bioventus Reports Upbeat Earnings, Joins Ranpak, Beachbody And Other Big Stocks Moving Higher On Tuesday | 1 | Benzinga.com | ||
12.03. | Bioventus Inc reports results for the quarter ended in December - Earnings Summary | - | Reuters | ||
12.03. | Bioventus Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
12.03. | Bioventus Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.03. | Bioventus Non-GAAP EPS of $0.07 beats by $0.05, revenue of $135.42M beats by $11.46M | 1 | Seeking Alpha | ||
12.03. | Bioventus, Inc.: Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results | - | GlobeNewswire (USA) | ||
11.03. | A Preview Of Bioventus' Earnings | 1 | Benzinga.com | ||
18.01. | Bioventus, Inc.: Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility | 261 | GlobeNewswire (Europe) | DURHAM, N.C., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it has entered... ► Artikel lesen | |
12.01. | Bioventus Inc. - 8-K, Current Report | 2 | SEC Filings | ||
12.01. | Bioventus, Inc.: Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole | 4 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EPIGENOMICS | 1,610 | -1,53 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,932 | -6,43 % | Ist es schon so weit? Raus aus KI, Biotech kaufen: Nvidia, Evotec, Defence Therapeutics und Bayer im Fokus | Wieder ein Schlag ins Kontor! Zum Monatsschluss April stürzt die Technologiebörse Nasdaq zum dritten Mal ab und zeigt mit 17.333 Punkten erneut große Schwäche. Nach einem langen Aufwärtstrend des NDX... ► Artikel lesen | |
GINKGO BIOWORKS | 0,975 | -1,32 % | GreenLab Partners with Ginkgo Bioworks to Scale Up Production of Brazzein, a Novel Sweetener | Plant Trait Services, Protein Services, and Deployment Capabilities JONESBORO, Ark. and BOSTON, May 7, 2024 /PRNewswire/ -- GreenLab, an emerging next generation plant-biotechnology company producing... ► Artikel lesen | |
BEAM THERAPEUTICS | 22,580 | -0,88 % | Beam Therapeutics Inc. - 10-Q, Quarterly Report | ||
RECURSION PHARMACEUTICALS | 8,665 | -3,08 % | Recursion (RXRX) to Report Q1 Earnings: What's in the Cards? | ||
ONCOLYTICS BIOTECH | 1,080 | -1,82 % | Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights | ||
ASSERTIO | 1,095 | -10,25 % | Assertio Holdings, Inc.: Assertio Reports First Quarter 2024 Financial Results | First Quarter Net Product Sales of $31.9 Million Rolvedon Growth Continues, with $14.5 million in Net Product Sales $7.5 Million in Cash Flow from Operations Increases Cash to $80.7 Million... ► Artikel lesen | |
ARCTURUS THERAPEUTICS | 27,570 | +0,92 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
SIGA TECHNOLOGIES | 10,460 | +0,67 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
MERRIMACK PHARMACEUTICALS | 15,050 | +0,23 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
VIR BIOTECHNOLOGY | 10,010 | -2,10 % | Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.
"We are excited... ► Artikel lesen | |
VERVE THERAPEUTICS | 6,230 | -2,96 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
ARS PHARMACEUTICALS | 9,340 | -1,16 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen | |
BIO-PATH | 2,805 | +3,51 % | Looking Into Bio-Path Holdings' Recent Short Interest | ||
BIOMEA FUSION | 12,300 | +0,33 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |